Immune Complex Glomerulonephritis in Hydralazine-Induced SLE

doi:10.1016/S0272-6386(84)80044-X

American Journal of Kidney Diseases

Volume 3, Issue 4, January 1984, Pages 270-274

https://doi.org/10.1016/S0272-6386(84)80044-X Get rights and content

Renal disease, a major feature of systemic lupus erythematosus (SLE), rarely occurs in drug-induced SLE. Immune complex glomerulonephritis has been demonstrated in a few cases of SLE following procainamide or anticonvulsant therapy but has not been documented in association with hydralazine-induced SLE despite the recognition of this syndrome 30 years ago. We report the clinical and renal pathologic findings in a patient with hydralazine-induced lupus nephritis and review the renal pathologic material in earlier reports of hydralazine-induced SLE.

Referencess (45)

V Agnello et al.
Immune complex systems in the nephritis of sytemic lupus erythematosus
Kidney Int
(1973)
HM Perry
Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis
Am J Med
(1973)
RT Schoen et al.
Drug-induced lupus: An adjuvant disease?
Am J Med
(1981)
MW McNicol et al.
Severe toxic reaction to hydralazine
Lancet
(1956)
WG Couser et al.
In situ immune complex formation and glomerular injury
Kidney Int
(1980)
S Björck et al.
Rapidly progressive glomerulonephritis after hydralazine
Lancet
(1983)
JD Morrow et al.
Studies on the control of hypertension by hyphex: II. Toxic reactions and side effects
Circulation
(1953)
R Gunther et al.
Das reversible procainamid-induzierte lupus-erythematodes-syndrome
Dtsch Med Wochenschr
(1969)
TS Whittle et al.
Procainamide-induced systemic lupus erythematosus
Arch Pathol Lab Med
(1976)
S Whittingham et al.
Systemic lupus erythematosus induced by procainamide
Austr Ann Med
(1970)

Y Levo et al.

Clinicopathologic study of a patient with procainamide-induced systemic lupus erythematosus

Ann Rheum Dis

(1976)

G Thoenes W Thoenes et al.

Drogen-induzierte Lupus-Nephritis

Verh Dtsch Ges Pathol

(1972)

L Eidus et al.

Screening of isoniazide inactivators

Antimicrob Agents Chemother

(1973)

A Weinstein

Drug induced systemic lupus erythematosus

Prog Clin Immunol

(1980)

D Alarcon-Segovia et al.

Clinical and experimental studies on the hydralazine syndrome and its relationship to SLE

Medicine

(1967)

GJ Dammin et al.

Hydralazine reaction: Case with LE cells antemortem and postmortem, and pulmonary, renal, splenic and muscular lesions of disseminated lupus erythematosus

J Lab Clin Med

(1955)

G Bendersky et al.

Hydralazine poisoning

JAMA

(1960)

HM Perry et al.

Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine

J Lab Clin Med

(1970)

R Lahita et al.

Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide

N Engl J Med

(1979)

RL Woosley et al.

Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome

N Engl J Med

(1978)

RH Heptinstall

AS Fauci et al.

The spectrum of vasculitis: Clinical, pathologic, immunologic, and therapeutic considerations

Ann Intern Med

(1978)

Cited by (21)

Drug-induced lupus
2015, Rheumatology: Sixth Edition
New-onset lupus nephritis in a kidney transplant recipient with cystinosis-differential diagnosis with cysteamine-induced lupus: Case report
2011, Transplantation Proceedings
Citation Excerpt :
DIL shares part of the classic symptoms and laboratory characteristics of SLE; however, several characteristics of SLE are usually absent in DIL, particularly nephritis. The renal disease on DIL is most often due to a necrotizing glomerulonephritis with little or no immune complex deposition,10,11 although an immune complex-mediated glomerulonephritis can occur.12 On the other hand, antihistone antibodies are present in over 95% of cases and are considered characteristic.
A case of lupus nephritis in an adult female kidney transplant recipient with cystinosis under cysteamine therapy is reported. Previous reports of new-onset lupus in cystinotic patients have focused in a possible relationship of lupus with cysteamine therapy, but no obvious pathophysiological association has been disclosed. The authors present a case of a 19-year-old female kidney transplant recipient with cystinosis admitted for acute allograft dysfunction, with clinical and immunologic manifestations of lupus nephritis. Cysteamine was considered as a potential cause of drug-induced lupus, and we temporarily interrupted this drug. The clinical picture, the negativity of antihistone antibodies, the nondisappearance of antinuclear antibodies after discontinuation of the drug, and the clinical stability after resuming cysteamine therapy suggested that the underlying mechanism of lupus was unrelated to the drug. This may be the first report of new-onset lupus in a kidney transplant recipient with cystinosis. Clinicians should be aware of the association of autoimmune abnormalities in patients with cystinosis.
Drug-Induced Disease
2011, Systemic Lupus Erythematosus
Autoimmunity can follow exposure to drugs or other agents. There are increasing numbers of reports and case series of patients who develop autoantibodies and lupus-like syndromes following exposure to certain medications and environmental agents, resulting in the development of drug-related lupus (DRL). The most frequently reported clinical features include constitutional symptoms, arthralgias/arthritis, serositis, and the development of autoantibodies. Systemic lupus erythematosus (SLE) is an autoimmune disease for which the etiology remains undetermined despite intensive research. There is evidence to suggest that genetic factors play a major role in the pathogenesis of this disease. The term “drug-related lupus” refers to the development of a lupus-like syndrome following exposure to a certain drug. An important feature of DRL is a temporal association between the ingestion of an agent and development of lupus-like features with remission of the features and decrease in autoantibody titers following withdrawal of the offending agent. Typical features of DRL include constitutional symptoms, arthralgias/arthritis, myalgias, serositis, elevated ESR, and a positive ANA, which is generally accepted as a requirement for the diagnosis. Specific clinical features for the diagnosis of DRL have not as yet been defined. There are as yet no established criteria for the diagnosis of DR and the definitive treatment is withdrawal of the offending agent. Physicians need to be aware of possible associations between the development of autoimmune-like features and exposure to certain pharmacologic agents for both diagnostic and therapeutic reasons.
Drug allergy: An updated practice parameter
2010, Annals of Allergy, Asthma and Immunology
Drug-Induced Disease
2010, Systemic Lupus Erythematosus, Fifth Edition
Autoimmunity can follow exposure to drugs or other agents. There are increasing numbers of reports and case series of patients who develop autoantibodies and lupus-like syndromes following exposure to certain medications and environmental agents, resulting in the development of drug-related lupus (DRL). The most frequently reported clinical features include constitutional symptoms, arthralgias/arthritis, serositis, and the development of autoantibodies. Systemic lupus erythematosus (SLE) is an autoimmune disease for which the etiology remains undetermined despite intensive research. There is evidence to suggest that genetic factors play a major role in the pathogenesis of this disease. The term “drug-related lupus” refers to the development of a lupus-like syndrome following exposure to a certain drug. An important feature of DRL is a temporal association between the ingestion of an agent and development of lupus-like features with remission of the features and decrease in autoantibody titers following withdrawal of the offending agent. Typical features of DRL include constitutional symptoms, arthralgias/arthritis, myalgias, serositis, elevated ESR, and a positive ANA, which is generally accepted as a requirement for the diagnosis. Specific clinical features for the diagnosis of DRL have not as yet been defined. There are as yet no established criteria for the diagnosis of DR and the definitive treatment is withdrawal of the offending agent. Physicians need to be aware of possible associations between the development of autoimmune-like features and exposure to certain pharmacologic agents for both diagnostic and therapeutic reasons.
Kidney Disease: Goodpasture's Disease, Lupus Nephritis, ANCA-Associated Glomerulonephritis
2006, The Autoimmune Diseases, Fourth Edition
This chapter discusses clinical, pathologic, epidemiologic, autoimmune, and genetic features of kidney diseases such as Goodpasture's disease, lupus nephritis, antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney diseases that are caused by autoimmune processes may result from: direct antibody-mediated attack against kidney antigens, immune complex deposition, or antibody-induced leukocyte activation, endothelial cell injury, and glomerulonephritis. Although many other kidney diseases are at least partially immune-mediated in nature, this chapter concentrates on these three diseases as the best examples of autoimmunity in the kidney. Anti-glomerular basement membrane (anti-GBM) disease is the only kidney disease in which it is definitely known that antibodies develop against a native renal antigen—the α3 helix of collagen IV. Currently, the pulmonary–renal syndrome can be caused by more than just anti-GBM disease and cryoglobulinemia, SLE, and systemic vasculitides, such as ANCA disease, are also potential culprits. The chapter also focuses on animal models, pathogenic mechanisms, immunologic markers in diagnosis, and treatment of these diseases.

View all citing articles on Scopus

: Supported in part by the National Institute of Arthritis, Metabolism and Digestive Diseases (Grant T2AM0708).

^b: Dr Shapiro's present address is Westchester County Medical Center, Valhalla, NY.

^c: Dr Pinn's present address is Department of Pathology, Howard University, Washington, DC.

View full text

Immune Complex Glomerulonephritis in Hydralazine-Induced SLE

Kidney Int

Am J Med

Am J Med

Lancet

Kidney Int

Lancet

Studies on the control of hypertension by hyphex: II. Toxic reactions and side effects

Circulation

Das reversible procainamid-induzierte lupus-erythematodes-syndrome

Dtsch Med Wochenschr

Procainamide-induced systemic lupus erythematosus

Arch Pathol Lab Med

Systemic lupus erythematosus induced by procainamide

Austr Ann Med

Clinicopathologic study of a patient with procainamide-induced systemic lupus erythematosus

Ann Rheum Dis

Drogen-induzierte Lupus-Nephritis

Verh Dtsch Ges Pathol

Screening of isoniazide inactivators

Antimicrob Agents Chemother

Drug induced systemic lupus erythematosus

Prog Clin Immunol

Clinical and experimental studies on the hydralazine syndrome and its relationship to SLE

Medicine

Hydralazine reaction: Case with LE cells antemortem and postmortem, and pulmonary, renal, splenic and muscular lesions of disseminated lupus erythematosus

J Lab Clin Med

Hydralazine poisoning

JAMA

Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine

J Lab Clin Med

Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide

N Engl J Med

Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome

N Engl J Med

The spectrum of vasculitis: Clinical, pathologic, immunologic, and therapeutic considerations

Ann Intern Med